This category needs an editor. We encourage you to help if you are qualified.
Volunteer, or read more about what this involves.
Related categories

175 found
Order:
1 — 50 / 175
  1. added 2018-11-30
    Disease Awareness Campaigns in Printed and Online Media in Latvia: Cross-Sectional Study on Consistency with WHO Ethical Criteria for Medicinal Drug Promotion and European Standards.Teresa Leonardo Alves, Elita Poplavska, Signe Mezinska, Ieva Salmane-Kulikovska, Liga Andersone, Aukje K. Mantel-Teeuwisse & Barbara Mintzes - 2018 - BMC Public Health 18 (18):1322.
    Background European legislation prohibits direct-to-consumer advertising of prescription medicines, but allows drug manufacturers to provide information to the public on health and diseases. Our aim was to measure the frequency of disease awareness campaigns in Latvian media and assess their compliance with international and European standards. Methods Materials on health/disease and treatments were collected between April and September 2015 from 12 newspapers and magazines and six online portals. Disease awareness campaigns were assessed using a previously developed instrument based on the (...)
    Remove from this list  
     
    Export citation  
     
    Bookmark  
  2. added 2018-10-31
    Context, Ethics and Pharmacogenetics.Adam M. Hedgecoe - 2004 - Studies in History and Philosophy of Biological and Biomedical Sciences 37 (3):566-582.
    Most of the literature on pharmacogenetics assumes that the main problems in implementing the technology will be institutional ones (due to funding or regulation) and that although it involves genetic testing, the ethical issues involved in pharmacogenetics are different from, even less than, ‘traditional’ genetic testing. Very little attention has been paid to how clinicians will accept this technology, their attitudes towards it and how it will affect clinical practice. -/- This paper presents results from interviews with clinicians who are (...)
    Remove from this list   Direct download  
     
    Export citation  
     
    Bookmark   1 citation  
  3. added 2018-09-21
    Coercion and the Neurocorrective Offer.Jonathan Pugh - forthcoming - In David Rhys Birks & Thomas Douglas (eds.), reatment for Crime: Philosophical Essays on Neurointerventions in Criminal Justice. Oxford, UK:
    According to what Douglas calls ‘the consent requirement’, neuro-correctives can only permissibly be provided with the valid consent of the offender who will undergo the intervention. Some of those who endorse the consent requirement have claimed that even though the requirement prohibits the imposition of mandatory neurocorrectives on criminal offenders, it may yet be permissible to offer offenders the opportunity to consent to undergoing such an intervention, in return for a reduction to their penal sentence. I call this the neurocorrective (...)
    Remove from this list   Direct download  
     
    Export citation  
     
    Bookmark  
  4. added 2018-09-21
    Smart Pills for Psychosis: The Tricky Ethical Challenges of Digital Medicine for Serious Mental Illness.Anna K. Swartz - 2018 - American Journal of Bioethics 18 (9):65-67.
  5. added 2018-09-21
    Zwischen Autonomie und Natürlichkeit. Der Begriff der Authentizität und die bioethische Debatte um das Neuro-Enhancement.Jon Leefmann - 2017 - Münster, Deutschland: Mentis.
    Hat die subjektive Erfahrung, uns selbst und anderen als eine bestimmte Person zu erscheinen, eine ethische Orientierungsfunktion? Und wenn ja, was geschieht, wenn wir uns auf eine Weise verändern, die uns an der Kontinuität dieser Erfahrung zweifeln lässt? Ausgehend von Schilderungen von Nicht-Authentizitäts-Erfahrungen wird in diesem Buch der Versuch unternommen, einen Begriff personaler Authentizität zu rekonstruieren, der für Fragen der angewandten Ethik handhabbar ist. Dabei verbindet das Buch auf innovative Weise zwei Diskussionsstränge aus der Bioethik und der praktischen Philosophie: die (...)
    Remove from this list  
    Translate
     
     
    Export citation  
     
    Bookmark  
  6. added 2018-06-11
    Review of Jessica Flanigan, Pharmaceutical Freedom. [REVIEW]Jonny Anomaly - 2018 - Notre Dame Philosophical Reviews:x-y.
    Remove from this list   Direct download  
    Translate
     
     
    Export citation  
     
    Bookmark  
  7. added 2018-06-04
    Love in the Time of Antibiotic Resistance: How Altruism Might Be Our Best Hope.Dien Ho - 2017 - In Philosophical Issues in Pharmaceutics: Development, Dispensing, and Use.
    Antibiotic-resistant bacteria pose a serious threat to our health. Our ability to destroy deadly bacteria by using antibiotics have not only improved our lives by curing infections, it also allows us to undertake otherwise dangerous treatments from chemotherapies to invasive surgeries. The emergence of antibiotic resistance, I argue, is a consequence of various iterations of prisoner’s dilemmas. To wit, each participant (from patients to nations) has rational self-interest to pursue a course of action that is suboptimal for all of us. (...)
    Remove from this list   Direct download  
     
    Export citation  
     
    Bookmark  
  8. added 2018-06-04
    Philosophical Issues in Pharmaceutics: Development, Dispensing, and Use.Dien Ho (ed.) - 2017 - Springer.
    This anthology provides a collection of new essays on ethical and philosophical issues that concern the development, dispensing, and use of pharmaceuticals. It brings together critical ethical issues in pharmaceutics that have not been included in any collection (e.g., the ethics of patients as researchers). In addition, it includes philosophical issues that are not within the traditional domain of applied ethics. For example, a game-theoretic approach to combating the emergence of antibiotic-resistent pathogens by spreading altruism. A tripartite distinction provides an (...)
    Remove from this list  
     
    Export citation  
     
    Bookmark  
  9. added 2018-06-02
    Run the Experiment, Publish the Study, Close the Sale: Commercialized Biomedical Research.Aleta Quinn - 2016 - De Ethica 2 (3):5-21.
    Business models for biomedical research prescribe decentralization due to market selection pressures. I argue that decentralized biomedical research does not match four normative philosophical models of the role of values in science. Non-epistemic values affect the internal stages of for-profit biomedical science. Publication planning, effected by Contract Research Organizations, inhibits mechanisms for transformative criticism. The structure of contracted research precludes attribution of responsibility for foreseeable harm resulting from methodological choices. The effectiveness of business strategies leads to overrepresentation of profit values (...)
    Remove from this list   Direct download  
     
    Export citation  
     
    Bookmark  
  10. added 2018-04-16
    Compensation for Cures: Why We Should Pay a Premium for Participation in ‘Challenge Studies’.Jonathan Anomaly & Julian Savulescu - forthcoming - Bioethics.
    Remove from this list   Direct download  
     
    Export citation  
     
    Bookmark  
  11. added 2018-02-26
    Social Policy and Cognitive Enhancement: Lessons From Chess.Emilian Mihailov & Julian Savulescu - 2018 - Neuroethics 11 (2):115-127.
    Should the development of pharmacological cognitive enhancers raise worries about doping in cognitively demanding activities? In this paper, we argue against using current evidence relating to enhancement to justify a ban on cognitive enhancers using the example of chess. It is a mistake to assume that enhanced cognitive functioning on psychometric testing is transferable to chess performance because cognitive expertise is highly complex and in large part not merely a function of the sum specific sub-processes. A deeper reason to doubt (...)
    Remove from this list   Direct download (3 more)  
     
    Export citation  
     
    Bookmark  
  12. added 2018-02-18
    INTRODUCTION: Pharmaceutical Firms and the Right to Health.Thana Cristina de Campos & Thomas Pogge - 2012 - Journal of Law, Medicine and Ethics 40 (2):183-187.
    Remove from this list   Direct download (4 more)  
     
    Export citation  
     
    Bookmark  
  13. added 2017-11-24
    Informatics: The Fuel for Pharmacometric Analysis.H. Grasela Thaddeus, Fiedler-Kelly Jill, Cirincione Brenda, Hitchcock Darcy, Reitz Kathleen, Sardella Susanne & Barry Smith - 2007 - AAPS Journal 9 (1):E84--E91.
    The current informal practice of pharmacometrics as a combination art and science makes it hard to appreciate the role that informatics can and should play in the future of the discipline and to comprehend the gaps that exist because of its absence. The development of pharmacometric informatics has important implications for expediting decision making and for improving the reliability of decisions made in model-based development. We argue that well-defined informatics for pharmacometrics can lead to much needed improvements in the efficiency, (...)
    Remove from this list   Direct download  
     
    Export citation  
     
    Bookmark  
  14. added 2017-05-17
    Harvesting the Uncollected Fruits of Other People’s Intellectual Labour.Cristian Timmermann - 2017 - Acta Bioethica 23 (2):259-269.
    Intellectual property regimes necessarily create artificial scarcity leading to wastage, both by blocking follow-up research and hindering access to those who are only able to pay less then the actual retail price. After revising the traditional arguments to hinder access to people’s intellectual labour we will examine why we should be more open to allow free-riding of inventive efforts, especially in cases where innovators have not secured the widest access to the fruits of their research and failed to cooperate with (...)
    Remove from this list   Direct download (3 more)  
     
    Export citation  
     
    Bookmark  
  15. added 2017-05-11
    Epistemology, Ethics, and Progress in Precision Medicine.Spencer Phillips Hey & Brianna Barsanti-Innes - 2016 - Perspectives in Biology and Medicine 59 (3):293-310.
    One of the central goals of precision medicine is to dissolve the long-standing tension between the population-level data provided by traditional randomized controlled trials and the physician’s need to prescribe therapies for their individual patient. The RCT can tell the physician that therapy A is, on average, more effective than therapy B for a population of patients, P, but this does not tell her whether A is more effective for the particular patient, p1, in front of her. However, by leveraging (...)
    Remove from this list   Direct download (2 more)  
     
    Export citation  
     
    Bookmark  
  16. added 2017-03-29
    Pharmacogenomic Inequalities: Strategies for Justice in Biomedical Research and Healthcare.Giovanni De Grandis - 2017 - Diametros 51:153-172.
    The paper discusses the possibility that the benefits of pharmacogenomics will not be distributed equally and will create orphan populations. I argue that since these inequalities are not substantially different from those produced by ‘traditional’ drugs and are not generated with the intention to discriminate, their production needs not be unethical. Still, the final result is going against deep-seated moral feelings and intuitions, as well as broadly accepted principles of just distribution of health outcomes and healthcare. I thus propose two (...)
    Remove from this list   Direct download (3 more)  
     
    Export citation  
     
    Bookmark  
  17. added 2016-12-15
    Review of Listening Into the Heart of Things-on MDMA and LSD by Samuel Widmer (1989).Michael Starks - 2016 - In Philosophy, Human Nature and the Collapse of Civilization -- Articles and Reviews 2006-2017 3rd Ed 686p(2017). Henderson,NV, USA: Michael Starks. pp. 573-575.
    This is an early volume from a much respected psychedelic psychotherapist. He has written several other books since this one but until recently none of his books were on Amazon and still you can only find a German edition and a Spanish one (from 1993) but no English one (except a couple used copies). This is sad since these drugs have enormous therapeutic potential but afaik government suppression still prevents their use. The most interesting and readable parts are the case (...)
    Remove from this list   Direct download  
     
    Export citation  
     
    Bookmark  
  18. added 2016-12-12
    MRCT Center Post-Trial Responsibilities Framework Continued Access to Investigational Medicines. Guidance Document. Version 1.0, December 2016.Carmen Aldinger, Barbara Bierer, Rebecca Li, Luann Van Campen, Mark Barnes, Eileen Bedell, Amanda Brown-Inz, Robin Gibbs, Deborah Henderson, Christopher Kabacinski, Laurie Letvak, Susan Manoff, Ignacio Mastroleo, Ellie Okada, Usharani Pingali, Wasana Prasitsuebsai, Hans Spiegel, Daniel Wang, Susan Briggs Watson & Marc Wilenzik - 2016 - The Multi-Regional Clinical Trials Center of the Brigham and Women’s Hospital and Harvard (MRCT Center).
    I. EXECUTIVE SUMMARY The MRCT Center Post-trial Responsibilities: Continued Access to an Investigational Medicine Framework outlines a case-based, principled, stakeholder approach to evaluate and guide ethical responsibilities to provide continued access to an investigational medicine at the conclusion of a patient’s participation in a clinical trial. The Post-trial Responsibilities (PTR) Framework includes this Guidance Document as well as the accompanying Toolkit. A 41-member international multi-stakeholder Workgroup convened by the Multi-Regional Clinical Trials Center of Brigham and Women’s Hospital and Harvard University (...)
    Remove from this list   Direct download (2 more)  
     
    Export citation  
     
    Bookmark  
  19. added 2016-12-12
    Who's in the Business of Saving Lives?Pepe Lee Chang - 2006 - Journal of Medicine and Philosophy 31 (5):465-482.
    There are individuals, including children, dying needlessly in poverty-stricken third world countries. Many of these deaths could be prevented if pharmaceutical companies provided the drugs needed to save their lives. Some believe that because pharmaceutical companies have the power to save lives, and because they can do so with little effort, they have a special obligation. I argue that there is no distinction, with respect to obligations and responsibilities, between pharmaceutical companies and other types of companies. As a result, to (...)
    Remove from this list   Direct download (6 more)  
     
    Export citation  
     
    Bookmark   6 citations  
  20. added 2016-12-08
    The Corporate Social Responsibility of Pharmaceutical Product Recalls: An Empirical Examination of U.S. And U.K. Markets. [REVIEW]Eng Tuck Cheah, Wen Li Chan & Corinne Lin Lin Chieng - 2007 - Journal of Business Ethics 76 (4):427-449.
    The pressure on companies to practice corporate social responsibility (CSR) has gained momentum in recent times as a means of sustaining competitive advantage in business. The pharmaceutical industry has been acutely affected by this trend. While pharmaceutical product recalls have become rampant and increased dramatically in recent years, no comprehensive study has been conducted to study the effects of announcements of recalls on the shareholder returns of pharmaceutical companies. As product recalls could significantly damage a company's reputation, profitability and brand (...)
    Remove from this list   Direct download (6 more)  
     
    Export citation  
     
    Bookmark   5 citations  
  21. added 2016-12-08
    Deadly Drugs and the Doctrine of Double Effect: A Reply to Tully.Lawrence Masek - 2006 - Journal of Business Ethics 68 (2):143-151.
    In a recent contribution to this journal, Patrick Tully criticizes my view that the doctrine of double effect does not prohibit a pharmaceutical company from selling a drug that has potentially fatal side-effects and that does not treat a life-threatening condition. Tully alleges my account is too permissive and makes the doctrine irrelevant to decisions about selling harmful products. In the following paper, I respond to Tully’s objections and show that he misinterprets my position and misstates some elements of the (...)
    Remove from this list   Direct download (5 more)  
     
    Export citation  
     
    Bookmark  
  22. added 2016-12-01
    Book Reviews : Abraham J 1995: Science, Politics and the Pharmaceutical Industry; Controversy and Bias in Drug Regulation. London: UCL Press . 308pp. £12.95 . ISBN 1 85728 200 0. [REVIEW]C. Agathangelou - 1996 - Nursing Ethics 3 (2):181-182.
    Remove from this list   Direct download (3 more)  
     
    Export citation  
     
    Bookmark  
  23. added 2016-10-03
    Liberal Forensic Medicine.Joseph Agassi - 1978 - Journal of Medicine and Philosophy 3 (3):226-241.
    The liberal approach to ethics quite naturally tends toward the classic individualistic theory of society, to reductionism or psychologism so-called, that is, to a reduction of all social action to individual action. For example, liberalism allows one to experiment with new medications on one's own body. By extension, liberalism allows one to experiment, it seems, on another person's body with new medication if one acts as the other person's agent, that is, if one has the other person's proper consent. We (...)
    Remove from this list   Direct download (6 more)  
     
    Export citation  
     
    Bookmark  
  24. added 2016-09-24
    Hormone Treatment of Children and Adolescents with Gender Dysphoria:An Ethical Analysis.Brendan S. Abel - 2014 - Hastings Center Report 44 (s4):S23-S27.
  25. added 2016-06-15
    Ethics, Antibiotics, and Public Policy.Jonny Anomaly - 2017 - Georgetown Journal of Law and Public Policy 15 (2).
    Remove from this list   Direct download  
    Translate
     
     
    Export citation  
     
    Bookmark  
  26. added 2016-05-15
    Análisis ético e implicaciones de la prolongación de los derechos de exclusividad sobre las invenciones farmacéuticas.Iván Vargas-Chaves - 2014 - Revista Jurídicas 11 (2):129-147.
    El presente artículo tiene como objetivo destacar la problemática de las prácticas de extensión o prolongación de los derechos de exclusividad sobre los medicamentos, llevadas a cabo por la industria farmacéutica, una vez el término de protección vía patente está por finalizar. A través de tres escenarios se pone de manifiesto las implicaciones de este fenómeno, destacándose la necesidad de involucrar activamente al Estado para garantizar así unas condiciones equitativas de acceso a los medicamentos.
    Remove from this list   Direct download  
    Translate
     
     
    Export citation  
     
    Bookmark  
  27. added 2015-09-20
    lfqjksfjlkqf qfnlqflfs.Qfqss Hakmo (ed.) - 24 January 2016 - dvdv.
    https://www.youtube.com/playlist?list=PLSD64sRy_MRN4G9mnfWKshXdgHD02n9Ag.
    Remove from this list   Direct download  
    Translate
     
     
    Export citation  
     
    Bookmark  
  28. added 2015-06-25
    The Politics and Bio-Ethics of Regulatory Trust: Case-Studies of Pharmaceuticals. [REVIEW]John Abraham - 2008 - Medicine, Health Care and Philosophy 11 (4):415-426.
    Drawing on case studies from the modern era of pharmaceutical regulation in the UK, US and Europe, I examine how the extent and distribution of trust between regulators, the pharmaceutical industry, and the medical profession about drug testing and monitoring influences knowledge and regulatory judgements about the efficacy and safety of prescription drugs. Introducing the concepts of ‘acquiescent’ and ‘investigative’ norms of regulatory trust, I demonstrate how investigative norms of regulatory trust—which deter pharmaceutical companies from assuming that their data analyses (...)
    Remove from this list   Direct download (3 more)  
     
    Export citation  
     
    Bookmark   1 citation  
  29. added 2015-05-21
    L'invention des maladies à but lucratif [On disease mongering].Rosangela Barcaro - 2014 - Arc En Ciel. La Revue de Nouveaux Droits de L’Homme (72):24-25.
  30. added 2015-03-17
    Pharmaceutical Company Funding and its Consequences: A Qualitative Systematic Review.Sergio Sismondo - manuscript
    This article systematically reviews published studies of the association of pharmaceutical industry funding and clinical trial results, as well a few closely related studies. It reviews two earlier results, and surveys the recent literature. Results are clear: Pharmaceutical company sponsorship is strongly associated with results that favor the sponsors' interests.
    Remove from this list   Direct download  
     
    Export citation  
     
    Bookmark   7 citations  
  31. added 2015-03-17
    The Psychiatrist and the Pharmaceutical Industry.Stephen A. Green - 2008 - In Sidney Bloch & Stephen A. Green (eds.), Psychiatric Ethics. Oxford University Press.
    Remove from this list  
     
    Export citation  
     
    Bookmark  
  32. added 2015-03-17
    Industry-to-Physician Marketing and the Cost of Prescription Drugs.Winston Chiong - 2003 - American Journal of Bioethics 3 (3):28 – 29.
    Remove from this list   Direct download (4 more)  
     
    Export citation  
     
    Bookmark  
  33. added 2015-03-17
    A Nonreductionist View of Knowledge: Product Development in the Pharmaceutical Industry.Alexander Styhre - 2000 - Emergence: Complexity and Organization 2 (3):51-67.
    Remove from this list   Direct download (3 more)  
     
    Export citation  
     
    Bookmark  
  34. added 2015-02-07
    Pharmaceuticals.Margit Sutrop & Kadri Simm - 2011 - In Ruth Chadwick, Henk ten Have & E. M. Meslin (eds.), SAGE Handbook of Healthcare Ethics. Sage Publications. pp. 427-439.
    This paper is concerned with analyzing transformations in the development, marketing, prescription, and access issues of pharmaceuticals, paying special attention to a variety of ethical and social aspects. A major focus of the article is on pharmacogenetics – a rapidly developing discipline which in the near future might well have a major effect on both drug development and clinical medicine.
    Remove from this list  
     
    Export citation  
     
    Bookmark  
  35. added 2014-11-01
    OAE: The Ontology of Adverse Events.Yongqun He, Sirarat Sarntivijai, Yu Lin, Zuoshuang Xiang, Abra Guo, Shelley Zhang, Desikan Jagannathan, Luca Toldo, Cui Tao & Barry Smith - 2014 - Journal of Biomedical Semantics 5 (29):1-13.
    A medical intervention is a medical procedure or application intended to relieve or prevent illness or injury. Examples of medical interventions include vaccination and drug administration. After a medical intervention, adverse events (AEs) may occur which lie outside the intended consequences of the intervention. The representation and analysis of AEs are critical to the improvement of public health. Description: The Ontology of Adverse Events (OAE), previously named Adverse Event Ontology (AEO), is a community-driven ontology developed to standardize and integrate data (...)
    Remove from this list   Direct download  
     
    Export citation  
     
    Bookmark   1 citation  
  36. added 2014-10-12
    Paying for the Possibility of Disease: How Medicalization of Risk Conditions Affects Health Policy and Why We Must Bear It In Mind.Alison Reiheld - 2008 - Medical Humanities Report:3, 4, 6.
    In this paper, I sound a warning note about the medicalization of risk conditions such as high cholesterol, especially in a health care climate of resource scarcity.
    Remove from this list   Direct download (2 more)  
    Translate
     
     
    Export citation  
     
    Bookmark  
  37. added 2014-08-04
    Enhancing Autonomy by Reducing Impulsivity: The Case of ADHD.Jonathan Pugh - 2014 - Neuroethics 7 (3):373-375.
    In a recent article in this journal, Schaefer et al. argue that it might be possible to enhance autonomy through the use of cognitive enhancements. In this article, I highlight an example that Schaefer et al. do not acknowledge of a way in which we already seem to be using pharmacological agents in a manner that can be understood as enhancing an agent’s autonomy. To make this argument, I begin by following other theorists in the philosophical literature in claiming that (...)
    Remove from this list   Direct download (2 more)  
     
    Export citation  
     
    Bookmark   3 citations  
  38. added 2014-08-04
    Will There Ever Be a Drug with No or Negligible Side Effects? Evidence From Neuroscience.Sylvia Terbeck & Laurence Paul Chesterman - 2014 - Neuroethics 7 (2):189-194.
    Arguments in the neuroenhancement debate are sometimes based upon idealistic scenarios involving the assumption of using a drug that has no or negligible side effects. At least it is often implicitly assumed – as technology and scientific knowledge advances - that there soon will be a drug with no or negligible side effects. We will review evidence from neuroscience, complex network research and evolution theory and demonstrate that - at least in terms of psychopharmacological intervention – on the basis of (...)
    Remove from this list   Direct download (4 more)  
     
    Export citation  
     
    Bookmark   2 citations  
  39. added 2014-07-12
    Ethical Considerations of Medical Cannabis Prescription.Cole Zachary - manuscript
    Despite analgesic and emetogenic benefits, cannabis has been banned from prescription in a number of western countries. Although some benefits are shared by drugs already available, the options of prescription are limited to the physician. The negative side-effects of cannabis do not justify this limitation on freedom and autonomy. Recreational use warrants limitations, as the search for euphoria is regularly believed to be a non-autonomous behavior. Medical prescriptions serve an analgesic and emetogenic purpose comparable to other prescribed drugs. This vindicates (...)
    Remove from this list   Direct download  
     
    Export citation  
     
    Bookmark  
  40. added 2014-04-02
    What's Wrong with Factory Farming?Jonny Anomaly - 2015 - Public Health Ethics 8 (3):246-254.
  41. added 2014-04-02
    Justice in Global Pandemic Influenza Preparedness: An Analysis Based on the Values of Contribution, Ownership and Reciprocity.Meena Krishnamurthy & Matthew Herder - 2013 - Public Health Ethics (3):pht027.
    In December 2006, Indonesia decided to stop sending influenza virus specimens to the World Health Organization’s Global Influenza Surveillance Network (GISN). Indonesia justified its actions by claiming that they were in protest of the injustice of GISN. Its actions stimulated negotiations to improve the workings of GISN by developing and implementing a more just framework for ‘sharing influenza viruses and other benefits’. These negotiations eventually led to the adoption of a new framework for virus and benefit sharing in May 2011, (...)
    Remove from this list   Direct download (9 more)  
     
    Export citation  
     
    Bookmark   1 citation  
  42. added 2014-04-02
    Postmodern Medicine: An Analysis of the Pharmaceutical Industry and Its Critics.S. Nassir Ghaemi - 2013 - Perspectives in Biology and Medicine 56 (2):223-235.
    There is an important cultural context to the relationship between physicians and the pharmaceutical industry. I'll label it, for simplicity, "postmodernism" (Kaplan 1993). Any single definition of a large cultural force, like socialism or communism or conservatism or liberalism, is bound to be inadequate in some ways. Yet general concepts can apply to such large forces. Postmodernism can have various nuances, but generally it applies to a way of thinking that is quite common nowadays: a skepticism about truth, knowledge, science, (...)
    Remove from this list   Direct download (6 more)  
     
    Export citation  
     
    Bookmark  
  43. added 2014-04-02
    Common Health Policy Interests and the Shaping of Global Pharmaceutical Policies.Meri Koivusalo - 2010 - Ethics and International Affairs 24 (4):395-414.
    In order to achieve more ethical global health outcomes, health policies must be driven by health priorities and should take into account broader health policy requirements, including the needs of specific national health systems. It is thus important to recognize that the division of interests in key policy areas are not necessarily between the priorities of rich and poor countries, but between pharmaceutical industry interests and health policy interests, and national industrial and trade policy interests and public health policies. In (...)
    Remove from this list   Direct download (9 more)  
     
    Export citation  
     
    Bookmark  
  44. added 2014-04-01
    Responsible Remedies.Mary Scott - 1994 - Business Ethics 8 (4):15-16.
    Shaman Pharmaceuticals seeks a cure for what ails the drug industry.
    Remove from this list   Direct download (5 more)  
     
    Export citation  
     
    Bookmark  
  45. added 2014-03-31
    An Engelhardtian Analysis of Interactions Between Pharmaceutical Sales Representatives and Physicians.J. F. Peppin - 1997 - Journal of Medicine and Philosophy 22 (6):623-641.
    Physician conflict of interest has been of concern since Hippocrates and rarely is this concern more evident than in the relationship between pharmaceutical sales representatives (PSR) and physicians. Given the acrimonious public debates concerning this issue a careful exploration of the concerns at sake and the conceptual arguments which support such concerns is called for. In this piece I will take as heuristic the conceptual philosophical framework argued for by H. Tristram Engelhardt. This framework would sanction interactions between PSRs and (...)
    Remove from this list   Direct download (6 more)  
     
    Export citation  
     
    Bookmark  
  46. added 2014-03-30
    Ethics, Pricing and the Pharmaceutical Industry.Richard A. Spinello - 1992 - Journal of Business Ethics 11 (8):617 - 626.
    This paper explores the ethical obligations of pharmaceutical companies to charge fair prices for essential medicines. The moral issue at stake here is distributive justice. Rawls'' framework is especially germane since it underlines the material benefits everyone deserves as Kantian persons and the need for an egalitarian approach for the distribution of society''s essential commodities such as health care. This concern for distributive justice should be a critical factor in the equation of variables used to set prices for pharmaceuticals.
    Remove from this list   Direct download (5 more)  
     
    Export citation  
     
    Bookmark   13 citations  
  47. added 2014-03-29
    Just Access to Health Care and Pharmaceuticals.Paul T. Menzel - 2010 - In George G. Brenkert & Tom L. Beauchamp (eds.), The Oxford Handbook of Business Ethics. Oxford University Press.
    Remove from this list  
     
    Export citation  
     
    Bookmark  
  48. added 2014-03-28
    Pharmaceutical Advertisements: How They Deceive Patients. [REVIEW]Ashish Chandra & Gary A. Holt - 1999 - Journal of Business Ethics 18 (4):359 - 366.
    Pharmaceutical advertising is one of the most important kinds of advertising that can have a direct impact on the health of a consumer. Hence, this necessitates the fact that it is essential for advertisers of such products to take special care and additional responsibility when devising the promotional strategies of these products. In reality, it has been observed that pharmaceutical product advertisers often promoted their products to achieve their own goals at the potential risk of having an adverse effect on (...)
    Remove from this list   Direct download (5 more)  
     
    Export citation  
     
    Bookmark   5 citations  
  49. added 2014-03-27
    Three Reasons Why a Global Market in Pharmaceutical Products is Inherently Unjust.Søren Holm - 2000 - Journal of Social Philosophy 31 (4):391–400.
  50. added 2014-03-27
    Access to Experimental Drugs in Terminal Illness. Ethical Issues: Udo Schuklenk, New York, Pharmaceutical Products Press, 1998, 228 Pages, US$60. [REVIEW]A. Byrne - 2000 - Journal of Medical Ethics 26 (2):148-149.
    Remove from this list   Direct download (4 more)  
     
    Export citation  
     
    Bookmark  
1 — 50 / 175